Article

Cross-talk between the oestrogen receptor and the human epidermal growth factor receptor (HER) family : role in resistance to tamoxifen treatment in breast cancer

2006-01-01

Abstract excerpt

Tamoxifen is a potent anticancer agent and has long been the standard for adjuvant endocrine therapy in breast cancer in the United Kingdom. Despite this success, resistance to Tamoxifen is a significant clinical problem; almost all patients with metastatic disease experience progression and up to 20% of early breast cancer patients relapse whilst on adjuvant treatment. The primary mechanism of action of Tamoxifen...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2539af94-6872-5647-9b93-62c63e6e4309
DOI: 10.5525/gla.thesis.71073

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Cross-talk between the oestrogen receptor and the human epidermal growth factor receptor (HER) family : role in resistance to tamoxifen treatment in breast cancerDOI 10.5525/gla.thesis.71073Read

Cross-Talk between Estrogen Receptor and Growth Factor Pathways as a Molecular Target for Overcoming Endocrine ResistanceSemantic proximity Read

Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy ResistanceSemantic proximity Read

Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer.Semantic proximity Read

Mechanisms of aromatase inhibitor resistance.Semantic proximity Read

Estrogen receptor mutations and changes in downstream gene expression and signaling.Semantic proximity Read

Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance.Semantic proximity Read

Thyroid hormone enhances estrogen-mediated proliferation and cell cycle regulatory pathways in steroid receptor-positive breast CancerSemantic proximity Read

New agents for endocrine resistance in breast cancer.Semantic proximity Read

Drug resistance to targeted therapies: Déjà vu all over againSemantic proximity Read

Resistance to Anti-HER2 Therapies in Breast CancerSemantic proximity Read

Endocrine therapy resistance: new insights.Semantic proximity Read

Clinical Evidence on the Magnitude of Change in Growth Pathway Activity in Relation to Tamoxifen Resistance is Required.Semantic proximity Read